Drugs Made In America Acquisition Corp. ( (DMAA) ) has released a notification of late filing.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Drugs Made In America Acquisition Corp. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The delay is primarily due to the inability to complete financial statements in time to obtain necessary reviews and signatures. The company anticipates that the report will be filed within five calendar days following the prescribed due date. There are no expected significant changes in financial results from the previous year, and the company is committed to maintaining compliance with filing requirements. The notification was signed by Lynn Stockwell, the Chief Executive Officer.
More about Drugs Made In America Acquisition Corp.
Average Trading Volume: 190,807
Current Market Cap: $235.6M
For an in-depth examination of DMAA stock, go to TipRanks’ Stock Analysis page.